AstraZeneca (NYSE: AZN) announced it has completed patient enrollment approximately four months ahead of plan in the Phase III clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE